CHK1 inhibitors administered to cancer patients to enhance the DNA damaging agent is provided. For example, for administration to a cancer patient and a 926CHK1 inhibitor, was carried out after administration of the DNA damaging agent the administration of the CHK1 inhibitor above, in 2 doses a CHK1 inhibitor said to enhance the DNA damaging agent administered to two days after the DNA damage factor the second dose of the CHK1 inhibitor administered, and was administered one day after the DNA damage factor the first dose of CHK1 inhibitor said, 926CHK1 inhibitor There are provided. None [Selection Figure]DNA損傷因子を増強するために癌患者に投与するCHK1阻害剤が提供される。例えば、DNA損傷因子を増強するために癌患者に投与するための’926CHK1阻害剤であって、前記CHK1阻害剤の投与を前記DNA損傷因子の投与後に行い、前記CHK1阻害剤を2回用量で投与し、前記CHK1阻害剤の1回目の用量を前記DNA損傷因子の1日後に投与し、かつ前記CHK1阻害剤の2回目の用量を前記DNA損傷因子の2日後に投与する、’926CHK1阻害剤が提供される。【選択図】なし
